Pacira Biosciences
10578 Science Center Drive
Suite 125
San Diego
California
92121
United States
Tel: (858) 625 2424
Website: http://www.pacira.com/
About Pacira Biosciences
At Pacira BioSciences, we have a capable and passionate team of people dedicated to serving our customers in a work environment that encourages collaboration. Our culture inspires and challenges individuals to be effective and efficient in all that they do, and our workforce has a passion for excellence.
OWNERSHIP: Public
Stock Exchange: NASDAQ
STOCK SYMBOL: PCRX
194 articles about Pacira Biosciences
-
Pacira Release: New Data Demonstrate Reduced Opioid Requirements Following Use Of EXPAREL In Hysterectomy And Mastectomy Procedures
3/24/2015
-
Pacira To Present At The Barclays Global Healthcare Conference
3/5/2015
-
Shares Fall as the FDA Rejects Pacira's Application for Expanded Use of Pain Drug
3/3/2015
-
Pacira Pharmaceuticals, Inc. Receives Complete Response Letter From FDA For sNDA Seeking Approval Of EXPAREL Use In Nerve Block To Provide Postsurgical Analgesia
3/2/2015
-
Pacira Pharmaceuticals, Inc. Clears Up EXPAREL-Related FDA Warning Letter
2/11/2015
-
Pacira Pharmaceuticals, Inc. To Host Analyst & Investor Day On Jan. 22 In New York
1/9/2015
-
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue Of $61.8 Million And Estimated Full-Year Total Revenue Of $197.7 Million
1/8/2015
-
Pacira Pharmaceuticals, Inc. Announces Changes To EXPAREL® Label
12/12/2014
-
Pacira Pharmaceuticals, Inc. To Present At The 26th Annual Piper Jaffray Healthcare Conference
11/25/2014
-
Pacira Pharmaceuticals, Inc. To Present At The Jefferies and Co. 2014 Global London Healthcare Conference
11/11/2014
-
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue Of $50.2 Million And Third Quarter 2014 Results
10/30/2014
-
Pacira Pharmaceuticals, Inc. Release: New Study Correlates Use Of EXPAREL For Postsurgical Pain Management With Significant Reductions In Opioid Related Adverse Events
10/28/2014
-
Pacira Pharmaceuticals, Inc. Announces Timing For Third Quarter 2014 Financial Results Webcast And Conference Call
10/15/2014
-
Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety Of EXPAREL® In Peripheral Nerve Block
10/14/2014
-
FDA Slaps Pacira Pharmaceuticals, Inc. With Warning Letter
9/26/2014
-
Pacira Pharmaceuticals, Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference
8/5/2014
-
Pacira Pharmaceuticals, Inc. Announces Timing For Second Quarter 2014 Financial Results Webcast And Conference Call
7/17/2014
-
Pacira Pharmaceuticals, Inc. Announces Publication Of Pooled Results From IMPROVE Studies Evaluating Health Economic Benefits Of EXPAREL®
6/26/2014
-
Pacira Pharmaceuticals, Inc. Announces sNDA Submission For EXPAREL Nerve Block Indication
5/7/2014
-
Pacira Pharmaceuticals, Inc. To Present At The Bank of America Merrill Lynch 2014 Health Care Conference
5/6/2014